A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer
- PMID: 20378504
- DOI: 10.3816/CCC.2010.n.014
A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer
Abstract
Introduction: This phase II trial evaluated the efficacy and safety of cetuximab combined with FOLFOX6 (leucovorin [LV] 5-fluorouracil [5-FU]/oxaliplatin) in the first-line treatment of patients with advanced or metastatic colorectal cancer.
Patients and methods: Patients with locally advanced or metastatic CRC who had received no previous therapy for advanced disease were treated with cetuximab at a loading dose of 400 mg/m2 followed by 250 mg/m2 weekly and a FOLFOX6 regimen every 2 weeks consisting of oxaliplatin 85 mg/m2, LV 400 mg/m2, and 5-FU bolus 400 mg/m2 followed by 5-FU continuous infusion 2400 mg/m2 over 46 hours.
Results: A total of 82 eligible patients were enrolled; epidermal growth factor receptor expression was positive in 67 patients. The overall response rate was 44.8%. In addition, 30 patients (44.8%) in the evaluable population experienced stable disease. Median time to progression or death was 9.3 months (95% CI, 7.0-11.3 months), and median survival was 21.7 months (95% CI, 17.5-27.8 months). Patients who experienced skin toxicity had a statistically significant and longer median survival time than those patients with no skin toxicity (P = .0001). The most commonly observed toxicities were neutropenia (65%), fatigue (56.3%), diarrhea (53.8%), nausea (50%), acneiform rash (41.3%), and stomatitis (35%).
Conclusion: Our results demonstrate that cetuximab can be safely combined with FOLFOX6 for the first-line treatment of patients with metastatic CRC (mCRC). The efficacy parameters are similar to other first-line regimens in mCRC. Because of the emergence of KRAS as a predictive marker, this regimen has promise in KRAS wild-type mCRC.
Similar articles
-
Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the first-line treatment of metastatic colorectal cancer.Clin Adv Hematol Oncol. 2010 Jul;8(7):480-5, 498. Clin Adv Hematol Oncol. 2010. PMID: 20864916 Clinical Trial.
-
Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer.Clin Colorectal Cancer. 2012 Jun;11(2):101-11. doi: 10.1016/j.clcc.2011.05.006. Epub 2011 Nov 4. Clin Colorectal Cancer. 2012. PMID: 22055112 Clinical Trial.
-
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.J Clin Oncol. 2010 Nov 1;28(31):4697-705. doi: 10.1200/JCO.2009.27.4860. Epub 2010 Oct 4. J Clin Oncol. 2010. PMID: 20921465 Clinical Trial.
-
Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.Clin Transl Oncol. 2010 Aug;12(8):533-42. doi: 10.1007/s12094-010-0551-3. Clin Transl Oncol. 2010. PMID: 20709651 Review.
-
Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.Clin Colorectal Cancer. 2008 Mar;7(2):110-7. doi: 10.3816/CCC.2008.n.015. Clin Colorectal Cancer. 2008. PMID: 18501070 Review.
Cited by
-
Non-Steroidal Anti-Inflammatory Drugs Increase Cisplatin, Paclitaxel, and Doxorubicin Efficacy against Human Cervix Cancer Cells.Pharmaceuticals (Basel). 2020 Dec 15;13(12):463. doi: 10.3390/ph13120463. Pharmaceuticals (Basel). 2020. PMID: 33333716 Free PMC article.
-
Effectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysis.Ecancermedicalscience. 2015 Oct 15;9:582. doi: 10.3332/ecancer.2015.582. eCollection 2015. Ecancermedicalscience. 2015. PMID: 26557880 Free PMC article. Review.
-
Systematic review on infusion reactions associated with chemotherapies and monoclonal antibodies for metastatic colorectal cancer.Curr Clin Pharmacol. 2012 Feb 1;7(1):56-65. doi: 10.2174/157488412799218806. Curr Clin Pharmacol. 2012. PMID: 22299770 Free PMC article.
-
Differences in symptom occurrence, severity, and distress ratings between patients with gastrointestinal cancers who received chemotherapy alone or chemotherapy with targeted therapy.J Gastrointest Oncol. 2017 Feb;8(1):109-126. doi: 10.21037/jgo.2017.01.09. J Gastrointest Oncol. 2017. PMID: 28280616 Free PMC article.
-
Combination therapy using oral S-1 and targeted agents against human tumor xenografts in nude mice.Exp Ther Med. 2012 May;3(5):755-762. doi: 10.3892/etm.2012.484. Epub 2012 Feb 13. Exp Ther Med. 2012. PMID: 22969964 Free PMC article.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous